Cupid Q1 FY27: Net profit triples, FY27 guidance up

Results that reset near-term expectations

Cupid Limited reported a sharp jump in profitability for Q1 FY27, supported by strong revenue growth and operating leverage. Consolidated revenue stood at ₹154.72 crore, up 28.98% quarter-on-quarter from ₹119.96 crore. On a year-on-year basis, revenue rose 158.73% compared with ₹59.80 crore in Q1 FY26. Net profit came in at ₹44.15 crore, a 21.76% QoQ increase from ₹36.26 crore, and a 194.14% rise from ₹15 crore a year ago. The company also said it expects revenue to exceed ₹150 crore for the April to June quarter, calling it among its strongest quarters.

Operating profit and margin expansion in focus

Operating profit for Q1 FY27 stood at ₹60.07 crore, climbing 60.14% QoQ from ₹37.51 crore. The same metric rose 264.72% YoY from ₹16.47 crore, reflecting a steep improvement in operating performance versus last year’s base. PBDT was reported at ₹61.21 crore, up 25.64% QoQ from ₹48.72 crore, with YoY growth of 194.42%. Profit before tax (PBT) rose to ₹59.92 crore, up 26.28% QoQ from ₹47.45 crore, and up 206.50% YoY.

Key quarterly numbers at a glance

The company disclosed both headline quarterly growth rates and absolute numbers for key profit lines. Revenue and profit trends were also reiterated through the “revenue from operations” and “total income” disclosures for Q1 FY27. Revenue from operations for Q1 FY27 was stated at ₹154.72 crore (₹15,471.50 lakh), while total income was ₹156.98 crore (₹15,698.01 lakh). Profit from ordinary activities before tax was ₹59.92 crore (₹5,991.87 lakh). These figures align with the Q1 FY27 performance highlights shared across multiple updates.

Stock reaction: gains over two days, dip on Monday

Cupid shares gained 8.8% in two days after the company reported a threefold rise in Q1 FY27 net profit to about ₹44 crore, alongside revenue growth of about 159% YoY to roughly ₹155 crore. Another market update noted the stock fell on Monday despite the same profit surge, as revenue rose 159% and EBITDA jumped 265%. The stock was described as a multibagger, with gains of 150% in 2026 and 683% over the past year, as per the cited market summary. The moves highlight that investor response can vary even when headline earnings are strong.

FY27 guidance raised to ₹725–750 crore revenue

A major part of the market focus has been Cupid’s upgraded FY27 outlook. The company enhanced its FY27 guidance to ₹725 crore to ₹750 crore in revenue and ₹210 crore to ₹225 crore in net profit. It also disclosed that initial targets set in May 2026 of ₹600 crore revenue and ₹180 crore profit for FY27 have been upgraded to the new ranges. Separately, management communicated a revised full-year FY27 revenue guidance of at least ₹660 crore versus an earlier target of ₹600 crore, describing this as an upward revision of a minimum of 10%. Another operational target mentioned was a net profit margin above 30%, alongside FY27 revenue of at least ₹600 crore in one update.

What management cited: exports, hedging, and demand mix

Cupid pointed to a favourable USD/INR environment that has supported export realizations. It also highlighted prudent hedging of currency exposure relating to international investments to help mitigate foreign exchange risk. The upgraded outlook was linked to a strong order book, healthy international B2B demand, and the expansion of its Consumer Healthcare and FMCG portfolio. The company also referred to expectations of robust performance during the second half of FY27 as part of its visibility narrative. These drivers were presented as factors behind the confidence to raise guidance.

Consumer Healthcare and FMCG contribution in FY26

The company disclosed that during FY26, its Consumer Healthcare and FMCG portfolio contributed revenue of ₹121.61 crore, comprising domestic sales. Management also indicated manufacturing initiatives, including dedicated production lines and interchangeable manufacturing lines, aimed at improving flexibility, supply reliability, tender participation, and operating leverage. The same set of updates linked these operating actions to the company’s ability to support growth across product categories and geographies. The guidance revision was repeatedly framed as being supported by order visibility and operating leverage.

FY26 recap: record year and AGM schedule

Cupid said FY26 was the strongest year in its history on a consolidated basis. For FY26, revenue from operations rose 94.9% to ₹357.71 crore, while total income increased 92.6% to ₹391.40 crore. EBITDA was reported at ₹116.70 crore, profit before tax at ₹142.47 crore, and profit after tax at ₹108.23 crore, with PAT up 164.7% year-on-year. The company said it surpassed its own guidance of ₹335 crore in revenue and ₹100 crore in PAT for FY26. Cupid also scheduled its 33rd Annual General Meeting for Tuesday, September 22, 2026 at 4:00 pm via Video Conferencing/Other Audio Visual Means, alongside the release of its FY26 annual report.

Medium-term aspiration: ₹1,500 crore by FY29

Alongside its FY27 guidance upgrade, Cupid set a medium-term aspiration to reach ₹1,500 crore in revenue by FY29. The company linked this goal to operational visibility across international B2B healthcare segments and a growing domestic consumer presence. While the FY29 target is longer-dated, it was positioned as part of the company’s broader planning cycle. The near-term focus, however, remains execution against the revised FY27 revenue and net profit ranges.

Why the update matters for investors

The Q1 FY27 print combines rapid year-on-year growth with a clear revision in full-year guidance, which can influence how investors frame the earnings base for FY27. Operating profit growth outpaced revenue growth, aligning with management’s emphasis on operating leverage. The guidance upgrade also provides a numeric anchor, with FY27 net profit now guided at ₹210–225 crore. Separately, the company’s emphasis on exports and currency risk management indicates that FX conditions remain a meaningful variable for realizations.

Conclusion

Cupid’s Q1 FY27 results showed revenue of ₹154.72 crore and net profit of ₹44.15 crore, alongside sharp growth in operating profit and pre-tax earnings. The company’s revised FY27 guidance of ₹725–750 crore revenue and ₹210–225 crore net profit is now the central reference point for tracking execution through the rest of the year. Investors will also track follow-through on manufacturing expansion and demand momentum across international B2B and the Consumer Healthcare and FMCG portfolio. The next formal checkpoint is the FY26 annual report release and the 33rd AGM scheduled for September 22, 2026.